MGLL (monoglyceride lipase) is a cytosolic lipid hydrolase that catalyzes the conversion of monoacylglycerols to free fatty acids and glycerol 12345. Its primary endocannabinoid-related function involves hydrolyzing 2-arachidonoylglycerol (2-AG), thereby regulating endocannabinoid signaling and pain perception 12345. Beyond endocannabinoid metabolism, MGLL generates fatty acid signaling molecules that promote cancer cell migration, invasion, and tumor growth 2. In disease contexts, MGLL dysfunction contributes to multiple pathologies. In renal fibrosis, MGLL deficiency leads to 2-AG accumulation and lipid-mediated tubular cell toxicity through CB2/β-catenin signaling; restoration of MGLL preserves fatty acid β-oxidation and protects against fibrogenesis 6. MGLL is significantly upregulated in pancreatic adenocarcinoma, promoting progression via the PI3K-AKT pathway and increased matrix metalloproteinase expression; melatonin may inhibit MGLL as a therapeutic approach 7. MGLL is downregulated during cancer cachexia, contributing to hepatic metabolic dysfunction 8. Genetic variants in MGLL modulate plasma LDL cholesterol levels and particle size response to omega-3 supplementation, suggesting involvement in lipoprotein metabolism 9.